(Total Views: 652)
Posted On: 04/01/2024 5:43:48 AM
Post# of 148870
Could you elaborate on this:
What was the thinking behind this post, so trials might not be necessary?
I think Dr. Lalezari was aware of leronlimab's anti-inflammatory capabilities through its MOA of CCR5/CCL5 axis blockade. He was aware of this for very long, but this generalized indication was never pursued. Then with the hold in place, and with the FDA coming down on them to find an indication in HIV that was not already met, this naturally came to the front of the class.
No doubt, this trial might be limited to the HIV population, but Phase III will be patients with Inflammation as a result of any primary disease, not just HIV.
From what I can gather, I believe you are thinking that as a result of the 2023 Patent, if any company wanted to use leronlimab in any of its forms as a blockade to the CCR5/CCL5 axis, then a license fee would be mandatory to be paid to CytoDyn. Is that correct?
So, when a certain patent does come to an end in about 50+ days, can we expect some companies to begin incorporating leronlimab into their technology and if so, the development of some revenue for CytoDyn?
Quote:
I read a post on a forum, poster mentioned possibly down the road, clinical trials may not even be necessary.
What was the thinking behind this post, so trials might not be necessary?
I think Dr. Lalezari was aware of leronlimab's anti-inflammatory capabilities through its MOA of CCR5/CCL5 axis blockade. He was aware of this for very long, but this generalized indication was never pursued. Then with the hold in place, and with the FDA coming down on them to find an indication in HIV that was not already met, this naturally came to the front of the class.
No doubt, this trial might be limited to the HIV population, but Phase III will be patients with Inflammation as a result of any primary disease, not just HIV.
From what I can gather, I believe you are thinking that as a result of the 2023 Patent, if any company wanted to use leronlimab in any of its forms as a blockade to the CCR5/CCL5 axis, then a license fee would be mandatory to be paid to CytoDyn. Is that correct?
So, when a certain patent does come to an end in about 50+ days, can we expect some companies to begin incorporating leronlimab into their technology and if so, the development of some revenue for CytoDyn?
(4)
(0)Scroll down for more posts ▼
